Two pharmaceutical drug manufacturers told a federal en banc appeals panel on Thursday that plaintiffs were trying to circumvent the U.S. Class Action Fairness Act, which requires that “mass actions” be tried in federal court, by coordinating dozens of cases in California state court.
The U.S. Court of Appeals for the Ninth Circuit panel, hearing arguments in Seattle on an issue of first impression, appeared reluctant to accept the drugmakers’ view, since doing so could force California’s judicial branch or legislators to change the language of a common court procedure used in mass torts.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
